Rallybio マネジメント

マネジメント基準チェック /24

Rallybioの CEO はSteve Udenで、 Jan2018年に任命され、の在任期間は 6.83年です。の年間総報酬は$ 1.78Mで、 29.8%給与と70.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.73%を直接所有しており、その価値は$ 776.66K 。経営陣と取締役会の平均在任期間はそれぞれ5.8年と4.1年です。

主要情報

Steve Uden

最高経営責任者

US$1.8m

報酬総額

CEO給与比率	29.8%
CEO在任期間	6.8yrs
CEOの所有権	1.7%
経営陣の平均在職期間	5.8yrs
取締役会の平均在任期間	4.1yrs

経営陣の近況

Recent updates

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

May 15

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Jan 30

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Oct 31

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Jul 07

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

Mar 16

CEO報酬分析

Rallybio の収益と比較して、Steve Uden の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$67m
Jun 30 2024	n/a	n/a	-US$74m
Mar 31 2024	n/a	n/a	-US$76m
Dec 31 2023	US$2m	US$530k	-US$75m
Sep 30 2023	n/a	n/a	-US$71m
Jun 30 2023	n/a	n/a	-US$71m
Mar 31 2023	n/a	n/a	-US$69m
Dec 31 2022	US$1m	US$491k	-US$67m
Sep 30 2022	n/a	n/a	-US$63m
Jun 30 2022	n/a	n/a	-US$55m
Mar 31 2022	n/a	n/a	-US$48m
Dec 31 2021	US$3m	US$441k	-US$47m
Sep 30 2021	n/a	n/a	-US$45m
Jun 30 2021	n/a	n/a	-US$42m
Mar 31 2021	n/a	n/a	-US$36m
Dec 31 2020	US$838k	US$380k	-US$26m

報酬と市場: Steveの総報酬 ($USD 1.78M ) は、 US市場 ($USD 647.72K ) の同規模の企業の平均を上回っています。

報酬と収益: Steveの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Steve Uden (66 yo)

6.8yrs

在職期間

US$1,778,284

報酬

Dr. Stephen Uden, also known as Steve, MD, is Chief Executive Officer and Director of Rallybio, LLC since August 01, 2023 and serves as its President. Dr. Uden is a Co-Founder of Rallybio, LLC in 2018 and...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Martin MacKay	Co-Founder & Executive Chairman	6.8yrs	US$1.78m	1.73% $ 776.7k
Stephen Uden	Co-Founder	6.8yrs	US$1.78m	1.73% $ 776.7k
Jonathan Lieber	CFO & Treasurer	1.8yrs	US$1.91m	0.012% $ 5.4k
Steven Ryder	Chief Medical Officer	5.8yrs	US$1.27m	0.46% $ 207.8k

5.8yrs

平均在職期間

67yo

平均年齢

経験豊富な経営陣: RLYBの経営陣は経験豊富で経験豊富です（平均在職期間は5.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Martin MacKay	Co-Founder & Executive Chairman	6.8yrs	US$1.78m	1.73% $ 776.7k
Stephen Uden	Co-Founder	1.3yrs	US$1.78m	1.73% $ 776.7k
Ronald Hunt	Independent Director	6.8yrs	US$115.45k	0% $ 0
Robert Hopfner	Independent Director	4.7yrs	US$115.45k	0% $ 0
Christine Nash	Independent Director	2.6yrs	US$108.95k	0% $ 0
Helen Boudreau	Independent Director	4.2yrs	US$118.95k	0.058% $ 25.8k
Lucian Iancovici	Independent Director	4.5yrs	データなし	データなし
Paula Soteropoulos	Independent Director	4.1yrs	US$113.95k	0.058% $ 25.8k
Wendy Chung	Independent Director	2.3yrs	US$95.00k	0% $ 0
Hui Liu	Independent Director	2.6yrs	US$111.45k	0% $ 0

4.1yrs

平均在職期間

56.5yo

平均年齢

経験豊富なボード: RLYBの取締役会は経験豊富であると考えられます ( 4.1年の平均在任期間)。

Rallybio マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Rallybio Corporation, Annual General Meeting, May 15, 2024

Rallybio Corporation Announces Executive Changes

Rallybio Corporation Announces Chief Financial Officer Changes

High number of new directors

Rallybio Corporation Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors

Rallybio Corporation Announces Retirement of Jeffrey Fryer as Chief Financial Officer

Recent updates

Rallybio Corporation Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Consensus revenue estimates increase by 33%

Rallybio Corporation Announces Initiation of Phase 2 Clinical Trial of RLYB212

Consensus EPS estimates upgraded to US$1.34 loss

New minor risk - Profitability

Rallybio Announces Publication of RLYB212 Phase 1 Proof-Of-Concept Study Results in Thrombosis and Haemostasis

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

Price target decreased by 19% to US$10.50

Rallybio Corporation(NasdaqGS:RLYB) dropped from Russell 3000 Index

Rallybio Corporation Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Rlybocytopenia

Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting

Rallybio Corporation, Annual General Meeting, May 15, 2024

Rallybio Corporation announced that it has received $6.599999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.38

Rallybio Corporation Announces the Prioritization of Its Portfolio and a 45% Workforce Reduction to Focus Resources on Its Phase 2-Ready Clinical Stage Programs

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Rallybio Corporation Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116

Rallybio Corporation Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212

New major risk - Share price stability

New minor risk - Market cap size

Rallybio Corporation Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Rallybio Corporation Presents Phase 1 Single Ascending Dose Data for RLYB116, Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Price target decreased by 7.3% to US$16.83

Rallybio Corporation Announces Executive Changes

Rallybio Corporation Reports Data from the Phase 1b Proof-Of-Concept Study of RLYB212

Price target decreased by 9.9% to US$18.17

Rallybio to Present Data from the RLYB212 Phase 1b Proof-Of-Concept Study

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Price target decreased by 7.2% to US$22.50

Rallybio Corporation Announces Chief Financial Officer Changes

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Rallybio Announces Publication of Data Highlighting the Ability of HPA-1A-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT

Price target decreased to US$28.00

High number of new directors

Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Price target increased to US$30.67

Rallybio Corporation Expects to Discuss the Preliminary Platelet Elimination Data by the End of the Third Quarter of 2022

Rallybio Corporation Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio Corporation Announces Retirement of Jeffrey Fryer as Chief Financial Officer

High number of new directors

Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi

High number of new directors

Rallybio Corporation, Annual General Meeting, May 24, 2022

High number of new directors

Rallybio Corporation Announces Board Changes

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

CEO & Chairman recently bought US$103k worth of stock

High number of new directors

Rallybio Corporation Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24